Hope is renewed for the cell therapy industry in 2025 fuelled by a 30% year on year increase in investment, notably in the cases of Arsenal Bio, Enara Bio and AvenCell. Landmark approvals for solid tumors from Adaptimmune and Iovance, along with significant clinical progress from Adicet Bio and Cartesian Therapeutics all signify huge strides forward for the industry. Don’t sit back and watch. Join the 10^th Anniversary of the CAR-TCR Summit to reflect on a decade of progress whilst engaging in solutions-driven discussions that will empower you to tackle cell therapy development challenges to help shape the future of the field.

Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umoja Biopharma, this meeting will equip you to overcome challenges across the entire development landscape - spanning durability, manufacturing timelines, potency assay matrix, solid tumor targeting, biomarker data, high cost of goods, scale up and scale out, and more, to make rapid advancements in the clinic and beyond. This is your definitive annual industry touchpoint to unlock breakthrough platform technology, accelerate clinical translation, and streamline manufacturing to deliver life changing cell therapies for patients in oncology and beyond.

Whether your focus is on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, or Analytical Development you can expect to gain in-depth insights across the entire cell therapy value chain.

Is industry collaboration your priority? Take part in 15+ hours of dedicated networking, from drinks receptions, poster sessions, and pharma partnering mixers. Maximize your opportunity to meet key industry stakeholders and expand your network.